drugset / Trial / NCT00767507
Maintenance of Platelet Inhibition With Cangrelor
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
Timeline
- Start
- 2008-10
- Primary completion
- 2011-06
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cangrelor | Small molecule | 0.75 ug/kg | Intravenous |